Latest news: CF PharmTech, Inc.

10-06	109,754,801 Ordinary Shares of CF PharmTech, Inc. are subject to a Lock-Up Agreement Ending on 7-OCT-2026.	CI
10-06	261,025,586 H Shares of CF PharmTech, Inc. are subject to a Lock-Up Agreement Ending on 7-OCT-2026.	CI
09-30	Tranche Update on CF PharmTech, Inc.'s Equity Buyback Plan announced on December 30, 2025.	CI
09-28	CF PharmTech, Inc. commences an Equity Buyback Plan for 30,082,658 shares, representing 7.33% of its issued share capital, under the authorization approved on June 26, 2026.	CI
09-22	CF PharmTech Doses First Subject in Phase I Trial for Inhaled Lung Disease Drug	MT
09-21	Cf Pharmtech, Inc. Completes Enrollment and Dosing of First Healthy Volunteer in Phase I Clinical Trial of Icf004	CI
08-31	CF PharmTech, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-24	CF PharmTech, Inc. Announces Expansion of Indications of ICF001 Following Receipt of Implied Clinical Trial Approvals from the NMPA	CI
07-31	CF PharmTech Eyes HK$295 Million from Share Placement	MT
06-26	Cf Pharmtech, Inc. Announces Board and Supervisor Appointments, Effective June 26, 2026	CI
06-25	CF PharmTech, Inc.'s Equity Buyback announced on December 30, 2025, has expired with 1,397,000 shares, representing 0.38% for HKD 35.9 million.	CI
06-05	CF PharmTech Clears GMP Inspection for Suzhou Inhalation Drug Facility	MT
06-04	CF PharmTech, Inc. Inhalation Formulation Production Base Passes GMP Inspection in PIC/S Member Country	CI

More news

Managers and Directors: CF PharmTech, Inc.

Manager	Title	Age	Since
Wen Qing Liang CEO	Chief Executive Officer	60	2006-12-31
Li Li CTO	Chief Tech/Sci/R&D Officer	67	2020-08-31
Wei Wei DFI	Director of Finance/CFO	47	2021-11-14

Director	Title	Age	Since
Li Li BRD	Director/Board Member	67	2020-08-31
Wen Qing Liang CHM	Chairman	60	2006-12-31
Qi Li BRD	Director/Board Member	67	2020-08-31

More insiders

CF PharmTech, Inc. is a China-based company primarily the research and development, production and sale of respiratory drugs and other related medical products. The Companyâ€™s product portfolio primarily focused on respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. The Company's primary products include CF017, a budesonide suspension for inhalation targeting bronchial asthma, and CF018, an azelastine hydrochloride and fluticasone propionate nasal spray approved for allergic rhinitis. The Company mainly conducts its business in the domestic market.

Employees

625

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-11-04	HK$5.285	+4.24%	1,227,207
26-11-03	HK$5.070	-4.07%	1,881,675
26-11-02	HK$5.285	-0.28%	713,143
26-10-30	HK$5.300	-5.86%	1,007,900
26-10-29	HK$5.630	-0.09%	1,142,875

Delayed Quote Hong Kong S.E.

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - CF PharmTech, Inc.

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Hong Kong S.E. 03:08:10 2026-11-04 EST			5-day change	1st Jan Change
5.285 ^HKD	+4.24%		-6.21%	-84.90%

Market Cap	1.84B 2.17B 276M 247M 227M 206M 387M 26.16B 396M 2.71B 1.09B 13.81B 1.04B 1.01B 43.76B	P/E 2024 *	-	P/E 2025	4,780x
Enterprise Value	1.33B 1.57B 200M 178M 164M 149M 279M 18.91B 286M 1.96B 787M 9.98B 749M 733M 31.64B	EV / Sales 2024 *	-	EV / Sales 2025	28.8x
Free-Float	60.8%	Yield 2024 *	-	Yield 2025	-

1 day	+4.24%
1 week	-6.21%
Current month	-0.28%
1 month	-26.19%
3 months	-69.17%
6 months	-76.68%
Current year	-84.90%

1 week	4.93	5.88
1 month	4.93	7.3
Current year	4.93	39.5
1 year	4.93	39.5
3 years	4.93	48.8
5 years	4.93	48.8
10 years	4.93	48.8

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/28/26	Wen Qing Liang	Other	Chief Executive Officer	25,100	0.0077%
9/28/26	Li Li	Other	Founder	25,100	0.0077%
12/22/25	Wen Qing Liang	Other	Chief Executive Officer	6,500	0.0022%

CF PharmTech, Inc. Stock

Stocks

2652

CNE1000074R9

Pharmaceuticals

Valuation: CF PharmTech, Inc.

Chart: CF PharmTech, Inc.

Latest news: CF PharmTech, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: CF PharmTech, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CF PHARMTECH, INC.	+4.24%	-6.21%	-81.91%	-	276M
ELI LILLY AND COMPANY	-0.11%	+9.94%	+57.20%	+148.21%	1,255B
JOHNSON & JOHNSON	-1.62%	-0.95%	+42.90%	+75.88%	641B
ABBVIE INC.	-0.98%	-0.14%	+34.93%	+102.23%	505B
ROCHE HOLDING AG	-0.70%	-2.36%	+47.50%	+64.20%	381B
MERCK & CO., INC.	-2.49%	+2.01%	+75.38%	+39.94%	357B
NOVARTIS AG	-0.33%	+1.84%	+29.68%	+56.22%	303B
ASTRAZENECA PLC	-1.02%	+7.65%	+9.67%	+33.71%	286B
AMGEN INC.	-0.90%	+2.97%	+55.67%	+70.93%	249B
GILEAD SCIENCES, INC.	-1.68%	+5.27%	+37.21%	+105.26%	208B
Average	-0.56%	+1.66%	+30.82%	+77.40%	418.55B
Weighted average by Cap.	-0.90%	+3.90%	+46.66%	+93.49%

	2024	2025
Net sales	608M 715M 91.07M 81.36M 74.74M 67.88M 127M 8.63B 131M 892M 359M 4.55B 342M 335M 14.43B	433M 509M 64.81M 57.9M 53.19M 48.31M 90.72M 6.14B 92.99M 635M 255M 3.24B 243M 238M 10.27B
Net income	21.09M 24.8M 3.16M 2.82M 2.59M 2.36M 4.42M 299M 4.53M 30.96M 12.45M 158M 11.86M 11.61M 501M	2.48M 2.92M 372K 333K 306K 278K 521K 35.27M 534K 3.65M 1.47M 18.62M 1.4M 1.37M 59.01M
Net Debt	-275M -323M -41.21M -36.82M -33.82M -30.71M -57.68M -3.9B -59.13M -404M -162M -2.06B -155M -151M -6.53B	-511M -600M -76.52M -68.37M -62.8M -57.03M -107M -7.25B -110M -750M -302M -3.83B -287M -281M -12.13B